Regeneron Pharmaceuticals

Profile narrative

Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes therapeutic medicines for serious medical conditions. Its portfolio includes monoclonal antibody treatments and protein-based therapies targeting diseases in ophthalmology, immunology, oncology, and rare disorders. The company’s products are marketed in the United States and internationally through direct sales forces and partnerships with other pharmaceutical firms. Regeneron’s research pipeline emphasizes innovative biologics designed to address unmet medical needs.

A distinguishing characteristic of Regeneron is its proprietary VelocImmune and VelociSuite technologies, which enable rapid generation of fully human monoclonal antibodies and accelerate drug discovery. These platforms have contributed to the approval of several flagship products, such as Eylea for retinal diseases and Dupixent for inflammatory conditions, often developed in collaboration with major pharmaceutical partners. The firm also maintains a strong focus on scientific rigor, with numerous peer‑reviewed publications and a track record of meeting regulatory standards set by agencies like the U.S. Food and Drug Administration.

Structurally, Regeneron operates as an independent, publicly traded corporation listed on the NASDAQ under the ticker REGN. It is not a subsidiary of another entity and retains control over its research, development, and commercialization activities. The company’s headquarters are located in Tarrytown, New York, United States, reflecting its primary base of operations while it maintains additional facilities across the country and in select international locations to support clinical trials and manufacturing.

Incidents

1 incident linked to this organisation.